• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment.

作者信息

Smets I, Reyes S, Baker D, Giovannoni G

机构信息

Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.

Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.

出版信息

Mult Scler Relat Disord. 2021 May;50:102851. doi: 10.1016/j.msard.2021.102851. Epub 2021 Feb 21.

DOI:10.1016/j.msard.2021.102851
PMID:33636615
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7897403/
Abstract
摘要

相似文献

1
Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment.奥瑞珠单抗治疗后疫苗反应减弱凸显了治疗前进行免疫接种的必要性。
Mult Scler Relat Disord. 2021 May;50:102851. doi: 10.1016/j.msard.2021.102851. Epub 2021 Feb 21.
2
B cell depletion in the treatment of multiple sclerosis.B 细胞耗竭在多发性硬化症治疗中的应用。
Expert Opin Biol Ther. 2019 Mar;19(3):261-271. doi: 10.1080/14712598.2019.1568407. Epub 2019 Jan 23.
3
New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.新型抗 CD20 单克隆抗体治疗 B 细胞淋巴瘤。
BioDrugs. 2011 Feb 1;25(1):13-25. doi: 10.2165/11539590-000000000-00000.
4
Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.奥瑞珠单抗可耗竭多发性硬化症患者的 CD20⁺T 细胞。
Cells. 2018 Dec 28;8(1):12. doi: 10.3390/cells8010012.
5
Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.奥瑞珠单抗换用利妥昔单抗后，多发性硬化症患者首剂后出现迟发性中性粒细胞减少症。
Mult Scler Relat Disord. 2020 Aug;43:102155. doi: 10.1016/j.msard.2020.102155. Epub 2020 May 13.
6
Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.奥法木单抗作为类风湿关节炎及其他自身免疫性疾病中CD20靶向治疗的前景。 （注：原文中多了一个of，正确句子应该是“Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.” ）
Immunotherapy. 2016 Sep;8(9):1091-6. doi: 10.2217/imt-2016-0003.
7
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis.在多发性硬化症中，奥瑞珠单抗比利妥昔单抗更能消耗T淋巴细胞。
Mult Scler Relat Disord. 2021 Apr;49:102802. doi: 10.1016/j.msard.2021.102802. Epub 2021 Jan 28.
8
Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with Zr in Human Lymphoma Xenografts.评估 Zr 标记的新一代抗 CD20 抗体在人淋巴瘤异种移植模型中的疗效。
J Nucl Med. 2018 Aug;59(8):1219-1224. doi: 10.2967/jnumed.117.203299. Epub 2018 Jan 18.
9
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.奥瑞珠单抗与安慰剂治疗原发性进行性多发性硬化症。
N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.
10
CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.用于治疗多发性硬化症的 CD20 单克隆抗体：最新进展。
Expert Opin Biol Ther. 2019 Aug;19(8):829-843. doi: 10.1080/14712598.2019.1611778. Epub 2019 May 24.

引用本文的文献

1
Herpes Zoster Infections With Multiple Sclerosis Disease-Modifying Therapies: A Real-World Pharmacovigilance Study.使用多发性硬化症疾病修正疗法时的带状疱疹感染：一项真实世界药物警戒研究。
Neurol Clin Pract. 2025 Apr;15(2):e200462. doi: 10.1212/CPJ.0000000000200462. Epub 2025 Mar 11.
2
A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.奥密克戎变异株早期完全接种疫苗的多发性硬化症接受抗 CD20 治疗患者 COVID-19 后血清转换的回顾性评估。
Mult Scler Relat Disord. 2023 Mar;71:104574. doi: 10.1016/j.msard.2023.104574. Epub 2023 Feb 15.
3
Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast.SARS-CoV-2 疫苗在短期和长期免疫中的有效性：大流行对比的综合概述。
Int J Mol Sci. 2022 Jul 30;23(15):8485. doi: 10.3390/ijms23158485.
4
Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments.2018 年以来获批多发性硬化症药物的疗效和安全性及未来发展
CNS Drugs. 2022 Aug;36(8):803-817. doi: 10.1007/s40263-022-00939-9. Epub 2022 Jul 22.
5
Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?多发性硬化症的治疗挑战——醋酸格拉替雷还有继续发挥作用的空间吗？
Front Neurol. 2022 Apr 15;13:844873. doi: 10.3389/fneur.2022.844873. eCollection 2022.
6
Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications.COVID-19 疫苗接种对高效疾病修正治疗药物治疗多发性硬化症患者的血清转化。
Mult Scler Relat Disord. 2022 Apr;60:103719. doi: 10.1016/j.msard.2022.103719. Epub 2022 Mar 3.
7
Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies.多种疾病修饰疗法治疗的多发性硬化症患者对 COVID mRNA 疫苗的体液免疫反应特征。
Vaccine. 2021 Oct 1;39(41):6111-6116. doi: 10.1016/j.vaccine.2021.08.078. Epub 2021 Sep 2.